Want to see TSE:MPH full AI Analyst Report?
Medicure (MPH) AI Stock Analysis
Medicure
(TSXV:MPH)
Medicure's score of 51 is heavily suppressed by its deteriorating financial fundamentals and poor valuation, marked by massive margin contraction, deep unprofitability, and operating cash burn. While technical indicators demonstrate exceptionally strong upward price momentum, the severe underlying operational weaknesses limit the overall rating.
Medicure (MPH) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 44.88M
- Dividend Yield
- ―
- Average Volume (3M)
- 6,064
- Price to Earnings (P/E)
- -6.0
- Beta (1Y)
- 1.56
- Revenue Growth
- 38.25%
- EPS Growth
- -450.85%
- Country
- Canada
- Employees
- 25
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Medicure Business Overview & Revenue Model
Company Description
Medicure Inc. is a biopharmaceutical firm focused on developing, researching, and commercializing therapeutic solutions for cardiovascular conditions across Canada and the United States. Its product portfolio includes AGGRASTAT, an injectable glycopr...
How the Company Makes Money
Medicure makes money primarily by commercializing prescription pharmaceuticals, generating revenue from product sales to customers in its served markets (notably the United States and Canada). Its revenue model is typically driven by (1) net sales of...
Medicure Earnings Call Summary
The earnings call presented a mixed performance with growth in certain product lines and strategic acquisitions aimed at expansion. However, these were offset by significant challenges such as decreased AGGRASTAT revenue, increased costs, and a resulting negative EBITDA and net loss. The positive aspects of strategic growth were balanced by financial challenges.
Q4-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the conference call, Medicure provided guidance on its financial performance for the year ended December 31, 2024, highlighting several key metrics. The company reported net revenue of $21.9 million, a slight increase from $21.7 million in the previous year, but experienced a net loss of approximately $1 million or $0.10 per share, compared to a net loss of $922,000 or $0.09 per share in the prior year. AGGRASTAT revenue decreased to $8.1 million from $9.7 million due to pricing pressures from generics, while ZYPITAMAG revenue through traditional insurance increased to $3 million from $2.4 million, attributed to greater utilization through insurance formularies. Marley Drug's net revenue rose to $10.8 million from $9.6 million, driven by changes in product mix and increased ZYPITAMAG sales. Despite these increases, adjusted EBITDA was negative $437,000, down from $1.9 million the previous year, due to higher costs of goods and R&D expenses totaling $3.1 million primarily for the MC-1 PNPO clinical trial. The company also highlighted strategic acquisitions of Gateway Medical and West Olympia Pharmacy, aiming to expand its Retail Pharmacy operating segment and create synergies with Marley Drug. Additionally, Medicure remains focused on developing new products, including a novel drug related to MC-1, with significant market potential.
Medicure Financial Statement Overview
Summary
Medicure faces severe operational distress characterized by collapsing gross margins, substantial net losses, and accelerating cash burn. Although the company maintains a practically debt-free balance sheet and has seen recent top-line revenue growth, rapidly eroding equity and negative operating cash flows present critical fundamental risks.
Income Statement
25NegativeBalance Sheet
55NeutralCash Flow
20Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.08M | 28.86M | 21.91M | 21.69M | 23.07M | 21.74M |
| Gross Profit | 12.19M | 11.25M | 13.09M | 13.99M | 16.07M | 12.71M |
| EBITDA | -4.61M | -4.24M | 1.54M | 1.27M | 3.44M | 2.39M |
| Net Income | -7.45M | -7.10M | -1.04M | -922.00K | 1.36M | -727.00K |
Balance Sheet | ||||||
| Total Assets | 22.59M | 24.95M | 29.68M | 28.06M | 29.90M | 28.41M |
| Cash, Cash Equivalents and Short-Term Investments | 1.83M | 3.83M | 7.19M | 6.37M | 4.86M | 3.69M |
| Total Debt | 696.00K | 891.00K | 874.00K | 544.00K | 849.00K | 1.17M |
| Total Liabilities | 11.02M | 12.04M | 8.90M | 8.16M | 8.89M | 10.00M |
| Stockholders Equity | 11.57M | 12.91M | 20.78M | 19.90M | 21.00M | 18.41M |
Cash Flow | ||||||
| Free Cash Flow | -1.93M | -560.00K | 638.00K | 1.81M | 1.52M | 3.17M |
| Operating Cash Flow | -1.93M | -560.00K | 1.38M | 2.08M | 1.83M | 3.99M |
| Investing Cash Flow | -253.00K | -2.04M | -739.00K | -270.00K | -310.00K | -2.69M |
| Financing Cash Flow | -429.00K | -415.00K | -370.00K | -297.00K | -355.00K | -316.00K |
Medicure Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MPH, the sentiment is Positive. The current price of 4.45 is above the 20-day moving average (MA) of 3.87, above the 50-day MA of 2.98, and above the 200-day MA of 1.60, indicating a bullish trend. The MACD of 0.45 indicates Positive momentum. The RSI at 70.35 is Negative, neither overbought nor oversold. The STOCH value of 77.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MPH.
Medicure Peers Comparison
Overall Rating
TSE:MDP63Neutral- TSE:MPH51Neutral
TSE:XBRA48.75Neutral
TSE:PHRX41Neutral
TSE:AQS37.85Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:MDP | 63Neutral | CAD 154.93M | -45.35 | -4.69% | ― | -3.16% | -345.50% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TSE:MPH | 51Neutral | CAD 44.88M | -5.97 | -54.73% | ― | 38.25% | -450.85% |
| TSE:XBRA | 49Neutral | CAD 420.72K | -0.14 | -610.58% | ― | ― | ― |
| TSE:PHRX | 41Neutral | CAD 671.07K | -0.93 | 37.95% | ― | ― | -62.50% |
| TSE:AQS | 38Underperform | CAD 663.17K | 3.13 | -2.92% | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:MPH | Medicure Inc | 4.23 | 3.01 | 245.31% | |
| TSE:AQS | Aequus Pharmaceuticals | 0.01 | 0.00 | 0.00% | |
| TSE:PHRX | Pharmadrug Inc. | 0.01 | -0.01 | -50.00% | |
| TSE:MDP | Medexus Pharmaceuticals | 4.84 | 2.15 | 79.93% | |
| TSE:XBRA | Xebra Brands Ltd. | 0.01 | 0.00 | 0.00% |
Medicure Corporate Events
Medicure Grants Stock Options to Key Personnel
NeutralMedicure Inc. has granted stock options to certain directors, officers, employees and consultants to purchase a total of 150,000 common shares at an exercise price of $2.88 per share. The options, issued under the company’s current stock option...
Medicure Completes Enrollment in Pivotal Phase 3 Trial for Ultra-Rare PNPO Deficiency
PositiveMedicure has completed patient enrollment in its pivotal MEND-PNPO Phase 3 clinical trial evaluating MC-1 for the treatment of Pyridox(am)ine 5′-Phosphate Oxidase deficiency, an ultra-rare neurometabolic disorder that causes severe seizures in...
Medicure Showcases Phase 3 PNPO Deficiency Trial as It Pushes Into Rare-Disease Therapies
PositiveMedicure has unveiled the design, rationale and baseline data from its pivotal Phase 3 MEND-PNPO study evaluating MC-1, an oral pharmaceutical-grade pyridoxal 5′-phosphate (P5P) therapy, for patients with genetically confirmed PNPO deficiency a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026